Researchers headed by a team at the California Institute of Technology developed an ultrasound-guided 3D printing technique ...

but does not penetrate the muscle layer), while 10% are diagnosed with a high-grade form of the diseaseknown as Carcinoma In-Situ (CIS) (disease which invades the bladder lining and can spread ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.